Crinetics Pharmaceuticals CRNX Available-for-Sale Debt Securities - Amortized Cost
Available-for-Sale Debt Securities - Amortized Cost at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost.
The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's available-for-sale debt securities - amortized cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's available-for-sale debt securities - amortized cost?
- Crinetics Pharmaceuticals (CRNX) reported available-for-sale debt securities - amortized cost of $718.48M in Q1 2026.
- What does available-for-sale debt securities - amortized cost mean?
- This is the cost basis of debt securities classified as available-for-sale, adjusted for amortization of premiums or discounts. It represents the value of the investment portfolio before accounting for current market price fluctuations. This provides a baseline for evaluating the performance of the company's liquid investment strategy.